Ranbaxy resolves tamsulosin patent dispute

New Delhi, Nov 8 (UNI) Pharma major Ranbaxy Laboratories Ltd today said it has resolved the US patent row over tamsulosin capsules.

Under the agreement, Ranbaxy will foray into the US market on March 2, 2010, two months before the patent expires and launch the drug 'on an exclusive basis', a company statement said.

Tamsulosin is used in the treatment of functional symptoms of BPH (benign prostatic hyperplasia).

Tamsulosin ANDA is the first substantially complete ANDA with a Paragraph IV certification to the '063 patent, the statement added.

The total annual sales of Flomax are estimated to be 1.2 billion dollars.

Ranbaxy Laboratories Ltd, an integrated, research-based, international pharmaceutical company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

UNI